TABLE 1.
Disease (A), donor and recipient (B) characteristics
| A. Disease characteristics | ||
|---|---|---|
| Disease stage | Initial diagnosis | Progressive disease |
| Date | January 1st, 2013 | December 1st, 2015 |
| (After 1st allogeneic HSCT) | ||
| Ig Subtype | IgA kappa | IgA kappa |
| Risk profile | Standard | High |
| International staging system (ISS) | 1 | Unknown |
| CRAB features | Osteolytic lesions and soft tissue‐like masses | Osteolytic lesions and soft tissue‐like masses |
| Durie‐Salmon staging system | IIIA | IIIA |
| Karyotype | 47, XY, +17 | 51, XY, + 3, + 9, + 11, + 15, + 17 |
| B. Donor and recipient characteristics | ||||||||
|---|---|---|---|---|---|---|---|---|
| HSCT | Donor | Stem cell source | CD34+ cells | Conditioning regimen | Immunosuppressive regimen | Blood group donor | Neutrophil engraftment | Platelet engraftment |
| 1st allogeneic HSCT | HLA‐matched sibling | PB and BM | 1.0 x 106/kg | Fludarabine 30 mg/m² (4 days) with melphalan 140 mg/m² (single dose) and ATG 10/20/30 mg/kg (Thymoglobulin, 3 days) | Cyclosporine 5 mg/kg and mycophenolate mofetil 2 g/day | A1 Rh‐ ccddee kk | Day +15 | Day +18 |
| 2nd allogeneic HSCT | HLA‐matched unrelated donor | PB | 5.5 x 106/kg | Fludarabine 30 mg/m² (4 days) with treosulfan 1400 mg/m² (3 days) and ATG 10/20/30 mg/kg (Thymoglobulin, 3 days) | Cyclosporine 5 mg/kg and mycophenolate mofetil 2 g/day | A2 Rh‐ ccddee kk | Day +28 | Not reached |